Edward Gane

Future hepatitis C virus treatment: interferon‐sparing combinations

E. Gane, Edward Gane, 2011, Liver international : official journal of the International Association for the Study of the Liver.

Sofosbuvir and ribavirin for 6 weeks is not effective among people with recent hepatitis C virus infection: The DARE‐C II study

Kathy Petoumenos, Margaret Hellard, Jason Grebely, 2016, Hepatology.

Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B.

Stefan Zeuzem, M. Buti, Y. Liaw, 2009, Journal of hepatology.

Sorafenib in advanced hepatocellular carcinoma.

Dieter Häussinger, Sergio Ricci, Armando Santoro, 2008, The New England journal of medicine.

Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B.

Huy Trinh, Robert Flisiak, Franck Rousseau, 2011, Gastroenterology.

Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study

John F. Flaherty, M. Washington, M. Buti, 2013, The Lancet.

Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial.

Thomas Berg, Stefan Zeuzem, Oliver Lenz, 2014, Gastroenterology.

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

Thomas Berg, Robert Flisiak, Philip McCloud, 2005, The New England journal of medicine.